Anniina T Virtanen (Anniina Virtanen)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Molecular Docking

Recombinant Human

Tyrosine Kinase

Top Venues

Science advances

Pharmaceuticals (Basel, Switzerland)

Arthritis & rheumatology (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Anniina T Virtanen, Maaria Palmroth, Sanna Liukkonen, Antti Kurttila, Teemu Haikarainen, Pia Isomäki, Olli Silvennoinen
In vitro profiling of rheumatic-disease-evaluated JAK inhibitors demonstrate differences in JAK isoform selectivity between different types of inhibitors. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)